Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TRIB 
Trinity Biotech plc (TRIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TRIB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.82% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.94M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 65970 | Beta 1.21 | 52 Weeks Range 0.56 - 3.55 | Updated Date 04/2/2025 |
52 Weeks Range 0.56 - 3.55 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -34.39% | Operating Margin (TTM) -14.65% |
Management Effectiveness
Return on Assets (TTM) -8.19% | Return on Equity (TTM) -1913.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 101815625 | Price to Sales(TTM) 0.18 |
Enterprise Value 101815625 | Price to Sales(TTM) 0.18 | ||
Enterprise Value to Revenue 1.72 | Enterprise Value to EBITDA -6.06 | Shares Outstanding 19194100 | Shares Floating 179775755 |
Shares Outstanding 19194100 | Shares Floating 179775755 | ||
Percent Insiders 12.4 | Percent Institutions 14.69 |
Analyst Ratings
Rating 5 | Target Price 7 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Trinity Biotech plc
Company Overview
History and Background
Trinity Biotech plc was founded in 1992. Initially focused on diagnostic antibodies, it expanded into clinical chemistry and infectious disease testing, growing through acquisitions and product development. The company has navigated challenges related to regulatory approvals and market competition to establish a global presence in the diagnostics industry.
Core Business Areas
- Clinical Chemistry: Offers a range of clinical chemistry reagents and instruments used for routine diagnostic testing in hospitals and clinical laboratories. Products include calibrators, controls, and reagents for analyzing blood and urine samples.
- Infectious Disease: Develops and manufactures diagnostic tests for infectious diseases such as HIV, sexually transmitted infections (STIs), and tropical diseases. Product offerings include ELISA kits, rapid tests, and molecular assays.
- Autoimmunity: Tests for autoimmune diseases such as celiac disease and rheumatoid arthritis.
Leadership and Structure
The company has a board of directors overseeing management. Specific details about the leadership team (CEO, CFO, etc.) are constantly changing. The organizational structure includes functional departments such as R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- HIV Rapid Tests: Rapid HIV tests provide point-of-care diagnosis. Market share data is fragmented, but Trinity Biotech is a significant player, especially in developing countries. Competitors include Abbott (ABT), bioMu00e9rieux, and Roche.
- Clinical Chemistry Reagents: A wide range of reagents for various clinical chemistry analyzers. Market share varies by region and specific test. Competitors include Siemens Healthineers, Roche, and Beckman Coulter.
- Celiac Disease Diagnostics: Tests for detecting celiac disease antibodies. Market share is growing as awareness of celiac disease increases. Competitors include Thermo Fisher Scientific and Euroimmun.
Market Dynamics
Industry Overview
The diagnostics industry is driven by aging populations, increasing prevalence of chronic diseases, and advancements in technology. The market is highly competitive, with both large multinational corporations and smaller specialized companies.
Positioning
Trinity Biotech occupies a niche position, focusing on specific diagnostic areas and geographic markets. It competes with larger players but also has specialized product offerings that provide a competitive edge. The company focuses on both developed and developing markets.
Total Addressable Market (TAM)
The global in vitro diagnostics market is estimated at several billion USD. Trinity Biotech's TAM is a subset of this, covering the infectious disease, clinical chemistry, and autoimmunity segments. They are positioned to serve both large centralized laboratories and smaller point-of-care settings.
Upturn SWOT Analysis
Strengths
- Established presence in niche diagnostic markets
- Strong product portfolio in specific disease areas
- Global distribution network
- Experienced management team
Weaknesses
- Smaller scale compared to major competitors
- Dependence on specific products and markets
- Potential for regulatory challenges
- Financial constraints and debt load
Opportunities
- Expansion into new geographic markets
- Development of innovative diagnostic technologies
- Strategic acquisitions to broaden product portfolio
- Partnerships with larger companies
Threats
- Intense competition from larger players
- Technological obsolescence
- Changes in regulatory requirements
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- ABT
- RO
- SI
Competitive Landscape
Trinity Biotech is smaller than its main competitors such as Abbott (ABT), Roche (RO), and Siemens Healthineers (SI). It focuses on niche markets. Its strengths are its specific product expertise. Its weaknesses are the large size and resources of its competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Trinity Biotech's historical growth has been a mix of organic growth and acquisitions. The company has faced challenges related to profitability and debt management.
Future Projections: Future projections are uncertain given the company's financial situation and market dynamics. Analyst estimates vary depending on the company's ability to execute its strategic plans.
Recent Initiatives: Recent initiatives have focused on cost reduction, product development, and market expansion.
Summary
Trinity Biotech occupied a niche position in the diagnostics market with a focus on infectious disease and clinical chemistry diagnostics. It faced stiff competition and had a high debt load. The key to success was in cost management and execution of strategic goals. Continued pressure from larger competitors in an increasingly competitive market was a significant concern.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
Sources and Disclaimers
Data Sources:
- Company filings (where available), Industry reports, Market research reports, Analyst reports, News articles
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trinity Biotech plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1995-08-18 | President, CEO, Company Secretary & Director Mr. John Gillard | ||
Sector Healthcare | Industry Medical Devices | Full time employees 380 | Website https://www.trinitybiotech.com |
Full time employees 380 | Website https://www.trinitybiotech.com | ||
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.